reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
== Natural occurrence == Safrole is the principal component of brown camphor oil made from Ocotea pretiosa, a plant growing in Brazil, and sassafras oil made from Sassafras albidum. In the United States, commercially available culinary sassafras oil is usually devoid of safrole due to a rule passed by the US FDA in 1960. Safrole can be obtained through natural extraction from Sassafras albidum and Ocotea cymbarum. Sassafras oil for example is obtained by steam distillation of the root bark of the sassafras tree. The resulting steam distilled product contains about 90% safrole by weight. The oil is dried by mixing it with a small amount of anhydrous calcium chloride. After filtering-off the calcium chloride, the oil is vacuum distilled at 100 °C under a vacuum of 11 mmHg (1.5 kPa) or frozen to crystallize the safrole out. This technique works with other oils in which safrole is present as well. Safrole is typically extracted from the root-bark or the fruit of Sassafras albidum (native to eastern North America) in the form of sassafras oil, or from Ocotea odorifera, a Brazilian species. Safrole is also present in certain essentials oils and in brown camphor oil, which is present in small amounts in many plants. Safrole can be found in anise, nutmeg, cinnamon, and black pepper. The safrole content of perfume, cologne, and eau de toilette can be determined by dilution with ethanol, followed by separation using high-performance liquid chromatography and quantization using spectrophotofluorometry.
Flagella are rigid protein structures, about 20 nanometres in diameter and up to 20 micrometres in length, that are used for motility. Flagella are driven by the energy released by the transfer of ions down an electrochemical gradient across the cell membrane. Fimbriae (sometimes called "attachment pili") are fine filaments of protein, usually 2–10 nanometres in diameter and up to several micrometres in length. They are distributed over the surface of the cell, and resemble fine hairs when seen under the electron microscope. Fimbriae are believed to be involved in attachment to solid surfaces or to other cells, and are essential for the virulence of some bacterial pathogens. Pili (sing. pilus) are cellular appendages, slightly larger than fimbriae, that can transfer genetic material between bacterial cells in a process called conjugation where they are called conjugation pili or sex pili (see bacterial genetics, below). They can also generate movement where they are called type IV pili. Glycocalyx is produced by many bacteria to surround their cells, and varies in structural complexity: ranging from a disorganised slime layer of extracellular polymeric substances to a highly structured capsule. These structures can protect cells from engulfment by eukaryotic cells such as macrophages (part of the human immune system). They can also act as antigens and be involved in cell recognition, as well as aiding attachment to surfaces and the formation of biofilms. The assembly of these extracellular structures is dependent on bacterial secretion systems.
OpenAI's Sam Altman said OpenAI would "do the same," though without specifying implementation details. Later OpenAI disclosed six additional instances of "concerning model behavior" identified since March 2026. In late September 2026, leaders and senior officials from 20 countries and the European Union signed a non-binding declaration calling for AI to remain under "human direction, oversight and control," for common international safety standards, and for incident reporting, and agreed to further explore establishing a global oversight institution. Notably, the United States and China did not sign the declaration.
Sources: en.wikipedia.org
Mackay snakehandler Ram Chandra traveled around Queensland and northern NSW, in part funded by the sugar industry. Sugarcane growers began to have trouble finding workers due to fears around the taipan. To counteract fears, the Queensland Cane Growers' Council produced an article in 1956 to calm panic, and Eric Worrell and David Fleay pointed out the snake's inherent shyness. In 1949 and 1950, 19-year-old snake handler Kevin Budden visited north Queensland to catch a taipan in a quest to develop antivenom. On 27 July 1950, he caught a specimen sunning itself in a rubbish dump on the outskirts of Cairns by putting his foot on it, grasping it by the neck with his left hand and letting it coil around his arm. He then walked to a main road and hailed a passing truck to take him to the house of local naturalist S.E. Stephens. Once there, the taipan escaped his grasp as he attempted to adjust his hold and bit his hand. Despite this, he secured the snake before going to hospital. He became paralysed later that day and succumbed early the following afternoon despite ventilation and large doses of tiger snake antivenom. Before he died, Budden requested the snake be sent to the Commonwealth Serum Laboratories, which in turn forwarded it to Fleay for milking. Fleay did so successfully, but found wrestling with the surprisingly strong and muscular subject to be difficult. They procured 78 mg of whitish venom, which led to the development of taipan antivenom. The snake itself became a minor celebrity, discussed in many newspapers at the time.
==== Legion number and title (cognomen) ==== The numbering of the legions is confusing, since several legions shared the same number with others. Augustus numbered the legions he founded himself from I, but also inherited numbers from his predecessors. Each emperor normally numbered the legions he raised himself starting from I. However, even this practice was not consistently followed. For example, Vespasian kept the same numbers as before for legions he raised from disbanded units. Trajan's first legion was numbered XXX because there were 29 other legions in existence at the time it was raised; but the second Trajanic legion was given the sequential number II. XVII, XVIII and XIX, the numbers of the legions annihilated in the Teutoburg Forest, were never used again. (These three legions are without titles, suggesting that in disgrace their titles may have been deliberately forgotten or left unmentioned.) As a result of this somewhat chaotic evolution, the legion's title became necessary to distinguish between legions with the same number. Legions often carried several titles, awarded after successive campaigns, normally by the ruling emperor e.g. XII Fulminata was also awarded: paterna (fatherly), victrix (victorious), antiqua (venerable), certa constans (reliable, steadfast) and Galliena (Gallienus '). Pia fidelis (loyal and faithful), fidelis constans and others were titles awarded to several legions, sometimes several times to the same legion. Only the most established, commonly used titles are displayed on this table. The geographical titles indicate
Observations in vitro and of tumours extracted from those five patients suggest that DCA might act against cancer cells by depolarising abnormal mitochondria found in glioblastoma cancer cells – allowing the mitochondria to induce apoptosis (cell death) of the malignant cells. In vitro work with DCA on neuroblastomas (which have fewer recognised mitochondrial abnormalities) showed activity against malignant, undifferentiated cells. A 2016 case report discussed and reviewed the application of DCA in central nervous system malignancies. A 2018 study found that DCA could trigger a metabolic switch from glycolysis (the Warburg effect) to mitochondrial OXPHOS and increase reactive oxygen stress affecting tumor cells. These effects were not observed in non-tumor cells. Current research has focused mainly on combining DCA with other cancer drugs to form prodrug complexes which can release both agents in a more targeted manner.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.